Reduction of elective lymph node volume in radiotherapy of early anal squamous cell cancer: a comparative study between two Swedish university hospitals
DOI:
https://doi.org/10.2340/1651-226X.2024.20336Keywords:
Anal cell carcinoma, chemoradiotherapy, pelvic irradiation, regional recurrence, external iliac lymph nodes, presacral lymph nodesAbstract
ABSTRACT
Background: Anal squamous cell cancer (ASCC) in early stages (T1–2N0M0) is treated with chemoradiotherapy with a 3-year overall survival (OS) exceeding 90%. In Swedish guidelines, it has been optional to include the external iliac and presacral lymph node (LN) stations in radiotherapy (RT) treatment fields in early ASCC. Two Swedish hospitals treating ASCC (SU: Sahlgrenska University Hospital; UU: Uppsala University Hospital) have chosen different approaches since 2010.
Material and methods: This study included consecutive patients with early ASCC (T1–2N0M0) treated between 2010 and 2017 at both sites (SU n = 70; UU n = 46). Data were retrieved from medical records and RT charts.
Results: At SU, the external iliac and presacral LN stations were included in elective LN irradiation in 96.8% (n = 60) and 95.2% (n = 59) patients compared to 2.4% (n = 1) and 29.3% (n = 12) at UU. The mean elective LN volume was 2,313 cc (interquartile range [IQR] 1,951–2,627) in the SU cohort compared to 1,317 cc (IQR 1,192–1,528) in the UU cohort, p < 0.0001. No case of regional LN recurrence was seen in either cohort. Disease specific survival (DSS) at 5 years was 95.7% (confidence interval [CI] 90.1–100.0) in the SU cohort and 97.8% (CI 93.2–100.0) in the UU cohort (p 0.55). OS at 5 years was 84.5% (CI 76.1–93.0) in the SU cohort and 82.6% (CI 69.6–89.1) in the UU cohort (p 0.8).
Interpretation: We found no differences in regional recurrence, DSS or OS between the cohorts treated with different elective LN volumes. In this population-based study, reduction of RT volume in early ASCC did not lead to inferior outcome.
Downloads
References
Vendrely V, Lemanski C, Pommier P, et al. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE. Radiother Oncol. 2023;183:109542.
https://doi.org/10.1016/j.radonc.2023.109542 DOI: https://doi.org/10.1016/j.radonc.2023.109542
Martin D, Schreckenbach T, Ziegler P, et al. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: a multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2022;167:233–8.
https://doi.org/10.1016/j.radonc.2021.12.050 DOI: https://doi.org/10.1016/j.radonc.2021.12.050
Bentzen AG, Guren M, Wanderås E, et al. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys. 2012;83(2):e173–80.
https://doi.org/10.1016/j.ijrobp.2011.12.062 DOI: https://doi.org/10.1016/j.ijrobp.2011.12.062
Nilsson MP, Nilsson ED, Johnsson A, et al. Patterns of recurrence in anal cancer: a detailed analysis. Radiat Oncol. 2020;15(1):125.
https://doi.org/10.1186/s13014-020-01567-7 DOI: https://doi.org/10.1186/s13014-020-01567-7
Ng M, Leong T, Chander S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–62.
https://doi.org/10.1016/j.ijrobp.2011.12.058 DOI: https://doi.org/10.1016/j.ijrobp.2011.12.058
Bisello S, Cilla S, Benini A, et al. Dose-volume constraints for organs at risk in radiotherapy (CORSAIR): an ‘all-in-one’ multicenter-multidisciplinary practical summary. Curr Oncol. 2022;29(10):7021–50.
https://doi.org/10.3390/curroncol29100552 DOI: https://doi.org/10.3390/curroncol29100552
Bentzen AG, Balteskard L, Wanderås EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52(4):736–44.
https://doi.org/10.3109/0284186X.2013.770599 DOI: https://doi.org/10.3109/0284186X.2013.770599
Leon O, Hagberg O, Johnsson A. Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin. Acta Oncol. 2018;57(9):1209–15.
https://doi.org/10.1080/0284186X.2018.1442931 DOI: https://doi.org/10.1080/0284186X.2018.1442931
Frennered A, Scherman J, Buchwald P, et al. Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes. BMC Cancer. 2021;21(1):447.
https://doi.org/10.1186/s12885-021-08187-8 DOI: https://doi.org/10.1186/s12885-021-08187-8
Ortholan C, Resbeut M, Hannoun-Levi J-M, et al. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 study). Int J Radiat Oncol Biol Phys. 2012;82(5):1988–95.
https://doi.org/10.1016/j.ijrobp.2011.02.010 DOI: https://doi.org/10.1016/j.ijrobp.2011.02.010
Slørdahl KS, Klotz D, Olsen J, Skovlund E, Undseth C, Abildgaard HL, et al. Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncol. 2021;60(7):921–30.
https://doi.org/10.1080/0284186X.2021.1918763 DOI: https://doi.org/10.1080/0284186X.2021.1918763
Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.
https://doi.org/10.1016/j.ijrobp.2006.12.052 DOI: https://doi.org/10.1016/j.ijrobp.2006.12.052
Johnsson A, Norman D, Angenete E, et al. Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results. Acta Oncol. 2022;61(5):575–82.
https://doi.org/10.1080/0284186X.2022.2048069 DOI: https://doi.org/10.1080/0284186X.2022.2048069
Thompson SR, Lee ISY, Carroll S, et al. Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ANZ J Surg. 2018;88(9):870–5.
https://doi.org/10.1111/ans.14398 DOI: https://doi.org/10.1111/ans.14398
Nilsson MP, Undseth C, Albertsson P, et al. Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer. Acta Oncol. 2023;62(8):897–906.
https://doi.org/10.1080/0284186X.2023.2240490 DOI: https://doi.org/10.1080/0284186X.2023.2240490
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sofia Heyman, Mats Perman, Calin Radu
This work is licensed under a Creative Commons Attribution 4.0 International License.
